Novartis is serving up $60 million to partner with Matchpoint Therapeutics in hopes of getting an oral covalent inhibitor ...

Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...

Swiss drugmaker Novartis will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs for several ...

The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” ...

Swiss pharmaceutical giant Novartis AG (NYSE:NVS) reported second-quarter 2025 earnings on Thursday and raised its full-year ...

The pharmaceutical company raised its full-year profit guidance as ongoing demand for key drugs fueled growth in ...

Swiss drugmaker Novartis nudged up its full-year earnings forecast on Thursday, citing strong second-quarter sales of key ...

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

Matchpoint Therapeutics said that it has signed an exclusive option and license agreement with Novartis (NYSE:NVS) to develop ...

Avalere Health, a 2025 MM+M Agency 100 honoree, named Rhiannon Meaden, PhD, as head of medical strategy and transformation.

Novartis is paying UCB $150 million up front to share in the development of two clinical-stage Parkinson’s disease drugs that offer new approaches to treating the disease. Depending on the ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research ...